| Kimberley W Brighton, CRNA | |
|
1501 E 3rd St, Delta, CO 81416-2815 | |
| (970) 874-7681 | |
| Not Available |
| Full Name | Kimberley W Brighton |
|---|---|
| Gender | Female |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 1501 E 3rd St, Delta, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124139118 | NPI | - | NPPES |
| 36925349 | Medicaid | CO | |
| BR675124 | Other | CO | BCBS |
| 840428757021 | Other | CO | ROCKY MOUNTAIN HEALTH PLA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 168736 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kimberley W Brighton, CRNA Po Box 10100, Delta, CO 81416-0008 Ph: (970) 874-2470 | Kimberley W Brighton, CRNA 1501 E 3rd St, Delta, CO 81416-2815 Ph: (970) 874-7681 |
News Archive
An enzyme that could represent a powerful new tool for combating Alzheimer's disease has been discovered by researchers at Mayo Clinic in Florida. The enzyme - known as BACE2 - destroys beta-amyloid, a toxic protein fragment that litters the brains of patients who have the disease.
Methodist DeBakey Heart & Vascular Center interventional cardiologists have, for the first time, repaired a large coronary artery aneurysm with stent-assisted coil embolization without doing open heart surgery.
Ipsen and Inspiration Biopharmaceuticals, Inc. announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion on the granting of orphan drug status for OBI-1 for the treatment of hemophilia.
Physician-scientists at University Hospitals Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine are leading a new study exploring the impact of exercise on outcomes for older breast cancer survivors.
Genta Incorporated has announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive. The data were featured in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 31, 2008.
› Verified 1 days ago
Mr. Carey B Simon, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-2255 | |
Clint B Pitchforth, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-7681 Fax: 970-874-6400 | |
Joseph Duane Mcbeain, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 236 Cottonwood St, Delta, CO 81416 Phone: 970-546-4010 Fax: 970-546-4016 | |
Christine A Hamilton, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-7681 | |
Kathy R Akers, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-7681 | |
Joshua Lake, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-7681 |